LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
July 31 2023 - 5:00AM
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care
diagnostics company, today announced that it signed a commercial
distribution agreement with Axon Lab AG (“Axonlab”) for the
commercialization of its LumiraDx Platform and diagnostic tests to
include exclusive distribution rights in Switzerland and additional
non-exclusive distribution rights in further European countries to
include and starting in Germany. Under the terms of the
distribution agreement, LumiraDx has granted Axonlab the right to
promote, market, and sell the LumiraDx Platform and tests to
hospitals, doctors, clinics, private laboratories and research
institutions in the aforementioned countries. The distribution
agreement is effective immediately. LumiraDx will continue its
direct sales programs in its many active markets across the globe.
Axonlab has dedicated diagnostics franchises and direct offices
in the countries covered under the distribution agreement and is
well positioned to accelerate the commercial success of the
LumiraDx Platform in Switzerland and Germany.
"We are excited to partner with LumiraDx for the commercial
distribution of the LumiraDx Platform in Switzerland and Germany,”
said Lukas Hadorn CEO of Axonlab. “LumiraDx clearly has shown to
have a unique technology with a broad, attractive menu of
diagnostic rapid tests, on an intuitive and simple to use
instrument, which allows these key tests to be performed in
doctors’ offices, clinics, and other testing sites at the
point-of-care. The LumiraDx Platform matches well into Axonlab’s
broad portfolio of point-of-care diagnostic solutions. In addition
to offering a diversified portfolio, Axonlab places great emphasis
on partnership-based customer relationships. We respond
individually to the needs of our customers and always strive to
implement segment specific solutions that suit best for all parties
involved.”
David Walton, LumiraDx’s Chief Commercial Officer commented "We
are pleased to announce our new partnership with Axonlab, whose
track record has shown that they are a fantastic partner for us in
these markets. With the new distribution agreement for Switzerland
and Germany, the Axonlab collaboration adds two important markets
to our distribution portfolio and will allow us to accelerate the
commercial roll-out of our unique LumiraDx Platform. LumiraDx
already has a strong commercial presence, either directly or
through our distribution partners, and we plan to continue
expanding this worldwide network through the addition of such major
commercial partnerships.”
About LumiraDxLumiraDx Limited (Nasdaq: LMDX)
is a next-generation point of care diagnostics company that is
transforming community-based healthcare. Its actively controlled
microfluidic technology provides fast, high performance and
accessible diagnostic solutions wherever the patient is for nearly
any testing scenario, creating unique testing options at the
point of need. The company offers a broad menu of lab comparable
tests on a single portable Platform, with more than 30 assays on
the market and in various stages of development, covering
infectious diseases, cardiovascular diseases, diabetes, and
coagulation disorders. The company also supports high-complexity
laboratory testing in an accessible high-throughput format to
leverage current molecular laboratory operations. Founded in 2014
and based in the UK, LumiraDx's diagnostic testing solutions are
being deployed globally by governments and leading healthcare
institutions across laboratories, urgent care, physician offices,
pharmacies, schools, and workplaces to help screen, diagnose, and
monitor wellness as well as disease. More information on LumiraDx
is available at www.lumiradx.com.
About Axonlab
Axonlab is a proactive and reliable partner of hospitals,
medical practices, private laboratories, research and industry, as
well as of private individuals. It is a cutting-edge,
customer-oriented service company operating in the fields of IVD,
Life Science and Medical IT for the healthcare sector and is a
leading company in the point-of-care solution business in Europe.
The company collaborates with reputable international supply
partners in selling innovative systems to clinics, doctors and the
research sector. Axonlab is focused on providing a comprehensive,
future-oriented service and to provide a foundation for long-term
business relations. Axonlab’s purpose to contribute to improving
healthcare for the people in Europe and to consequently contribute
to patients’ quality of life is firmly anchored in the DNA of the
company. Having been engaged with customers for more than 33 years
is why they know and understand their customer’s requirements
thoroughly.
Visit www.axonlab.com for more information.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, including statements regarding the
performance and benefits of the LumiraDx Instrument and tests,
the expected benefits of the distribution agreement with Axonlab,
and the timing of commercial launch and shipments of certain
products. These statements involve risks, uncertainties and other
factors that may cause actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements, including, among others, general economic, political
and business conditions; changes in interest rates, inflation rates
and global and domestic market conditions; the effect of COVID on
our business and financial results; obtaining or maintaining
regulatory approval, authorization or clearance for our tests; and
those factors discussed under the header “Risk Factors” in our
Annual Report on Form 20-F for the year ended December 31, 2022,
which was filed with the Securities and Exchange Commission, or
SEC, on May 1, 2023, and in other filings that we make with the
SEC. Although LumiraDx believes that it has a reasonable basis for
each forward-looking statement contained in this press release,
LumiraDx cautions you that these statements are based on a
combination of facts and factors currently known by it and its
projections of the future, about which it cannot be certain.
LumiraDx undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
*Not all tests are available in all countries and regions. For
additional detail on product availability please
visit www.lumiradx.com
Media Contact investors@lumiradx.com
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Apr 2024 to May 2024
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From May 2023 to May 2024